Once-Daily Amikacin Dosing In Burn Patients Treated With Continuous Venovenous Hemofiltration

Simple item page
dc.contributor.utaustinauthorFrei, Christopher R.en
dc.creatorAkers, Kevin S.en
dc.creatorCota, Jason M.en
dc.creatorFrei, Christopher R.en
dc.creatorChung, Kevin K.en
dc.creatorMende, Katrinen
dc.creatorMurray, Clinton K.en
dc.date.accessioned2015-09-09T15:51:20Zen
dc.date.available2015-09-09T15:51:20Zen
dc.date.issued2011-10en
dc.description.abstractAmikacin clearance can be increased in burn injury, which is often complicated by renal insufficiency. Little is known about the impact of renal replacement therapies, such as continuous venovenous hemofiltration (CVVH), on amikacin pharmacokinetics. We retrospectively examined the clinical pharmacokinetics, bacteriology, and clinical outcomes of 60 burn patients given 15 mg/kg of body weight of amikacin in single daily doses. Twelve were treated with concurrent CVVH therapy, and 48 were not. The pharmacodynamic target of >= 10 for the maximum concentration of drug in serum divided by the MIC (C-max/MIC) was achieved in only 8.5% of patients, with a small reduction of C-max in patients receiving CVVH and no difference in amikacin clearance. Mortality and burn size were greater in patients who received CVVH. Overall, 172 Gram-negative isolates were recovered from the blood cultures of 39 patients, with amikacin MIC data available for 82 isolates from 24 patients. A 10,000-patient Monte Carlo simulation was conducted incorporating pharmacokinetic and MIC data from these patients. The cumulative fraction of response (CFR) was similar in CVVH and non-CVVH patients. The CFR rates were not significantly improved by a theoretical 20 mg/kg amikacin dose. Overall, CVVH did not appear to have a major impact on amikacin serum concentrations. The low pharmacodynamic target attainment appears to be primarily due to higher amikacin MICs rather than more rapid clearance of amikacin related to CVVH therapy.en
dc.description.departmentPharmaceutical Sciencesen
dc.description.sponsorshipen
dc.identifier.citationAkers, K. S., Cota, J. M., Frei, C. R., Chung, K. K., Mende, K., & Murray, C. K. Once-Daily Amikacin Dosing In Burn Patients Treated With Continuous Venovenous Hemofiltration. Antimicrobial Agents and Chemotherapy, Vol. 55 No. 10 (Oct.,2011) pp. 4639–4642. doi:10.1128/AAC.00374-11en
dc.identifier.doi10.1128/aac.00374-11en
dc.identifier.issn0066-4804en
dc.identifier.urihttp://hdl.handle.net/2152/31194en
dc.identifier.urlen
dc.language.isoEnglishen
dc.relation.ispartofserialAntimicrobial Agents and Chemotherapyen
dc.rightsAdministrative deposit of works to Texas ScholarWorks: This works author(s) is or was a University faculty member, student or staff member; this article is already available through open access or the publisher allows a PDF version of the article to be freely posted online. The library makes the deposit as a matter of fair use (for scholarly, educational, and research purposes), and to preserve the work and further secure public access to the works of the University.en
dc.rights.holderen
dc.subjectrenal replacement therapyen
dc.subjectacute kidney injuryen
dc.subjectcalcoaceticus complexen
dc.subjectpharmacokineticsen
dc.subjectinfectionsen
dc.subjectresistanceen
dc.subjectregimensen
dc.subjectsepsisen
dc.subjectmicrobiologyen
dc.subjectpharmacology & pharmacyen
dc.titleOnce-Daily Amikacin Dosing In Burn Patients Treated With Continuous Venovenous Hemofiltrationen
dc.typeArticleen

Access full-text files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
OnceDailyAmikacinDosing.pdf
Size:
61.94 KB
Format:
Adobe Portable Document Format
Download

Collections

UT Faculty/Researcher Works